[A25-120] Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 10.12.2025
Project no.:
A25-120
Commission:
Commission awarded on 25.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Skin and hair
| Project no. | Title | Status |
|---|---|---|
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-65 | Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-121 | Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V | Commission work started |